MedTrace Logo

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.

NCT01197508 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 696

Last updated 2014-04-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like a medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.

Conditions

Interventions

DRUG

TC-5214

Twice daily for 8 weeks.

DRUG

Placebo

Twice daily for 8 weeks.

Sponsors & Collaborators

  • Targacept Inc.

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Hans A Eriksson, MD,PhD, MBA · AstraZeneca R&D

  • Hans-Jürgen Möller, Prof. Dr. · University Hospital München

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • Argentina
  • Brazil
  • Bulgaria
  • Chile
  • Colombia
  • Croatia
  • France
  • Germany
  • Hungary
  • Poland
  • Romania
  • Russia
  • Serbia
  • Slovakia
  • South Africa
  • Spain
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01197508 on ClinicalTrials.gov